Many here did not make a "speculative" investment decision about COVID-19. That came to us and management made the decision to go after it. The primary target was IPF and CC. How has that turned out for us thus far? Revisionist History is always a comforting thing to say but never the truthful thing to say. It's like feeding someone comfort food. It's good but eventually it will clog up your arteries.
I do not have Revisionist History. My history of posts here have waved the Red Flag about our inability to recruit patients in Australia and New Zealand. That was well before whatever organization AP joined in an attempt to increase the recruitment rate of 20 frigging people across two countries. The IPF/CC clinical trial has become a shame unto itself. If nothing comes of the COVID-19 clinical trial by way of outside financing, it will be the failure to execute the IPF./CC clinical trial in a reasonable time frame that will be the crux of massive dilution moving forward.
It's a colossal blunder at the feet of Christopher J. Moreau (CEO @ AP) that we continue to ignore at our own peril.
News 
Market Data 
Discover 
